Accéder au contenu
MilliporeSigma
Toutes les photos(1)

Key Documents

SAB2501521

Sigma-Aldrich

Anti-PCSK9 antibody produced in goat

affinity isolated antibody, buffered aqueous solution

Synonyme(s) :

Anti-FH3, Anti-HCHOLA3, Anti-LDLCQ1, Proprotein convertase subtilisin/kexin type 9

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Code UNSPSC :
12352203
Nomenclature NACRES :
NA.41

Source biologique

goat

Conjugué

unconjugated

Forme d'anticorps

affinity isolated antibody

Type de produit anticorps

primary antibodies

Clone

polyclonal

Forme

buffered aqueous solution

Espèces réactives

mouse, human, rat

Technique(s)

indirect ELISA: suitable
western blot: suitable

Numéro d'accès UniProt

Q8NBP7

Conditions d'expédition

dry ice

Température de stockage

−20°C

Modification post-traductionnelle de la cible

unmodified

Informations sur le gène

human ... PCSK9(255738)

Description générale

PCSK9 (proprotein convertase subtilisin/Kexin Type 9) codes for a secretory serine protease predominantly expressed in liver and intestine. The PCSK9 gene is mapped to human chromosome 1p32.3 and is highly polymorphic.. PCSK9 is also expressed in vascular smooth muscle cells.

Immunogène

Peptide with sequence TRFHRQASKCDSHGT, from the internal region of the protein sequence according to NP_777596.2

Actions biochimiques/physiologiques

PCSK9 (proprotein convertase subtilisin/Kexin Type 9) promotes lysosomal degradation of LDLR (low density lipoprotein receptor), VLDL (very low density lipoprotein receptor) and LRP (LDL related protein) to cause clearance of plasma cholesterol. On the other hand, PCSK9 also stimulates the release of chylomicron in intestinal cells. Lower intracellular cholesterol and mutations such as gain of function stimulates the expression of PCSK9. Autosomal dominant hypercholesterolemia is a result of high LDLR-degradation caused due to mutated PCSK9. PCSK9 is known to prevent the entry and replication of hepatitis C virus. PCSK9 expression is observed in atherosclerotic plaques.

Caractéristiques et avantages

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Forme physique

Supplied at 0.5 mg/mL in 20mM Tris (pH 7.3) and 150mM NaCl with 0.02% sodium azide and 0.5% bovine serum albumin.

Clause de non-responsabilité

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Vous ne trouvez pas le bon produit ?  

Essayez notre Outil de sélection de produits.

Code de la classe de stockage

10 - Combustible liquids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study.
Ruscica M, et al.
Journal of the American Heart Association, 6(5), e005764-e005764 (2017)
The elevation of plasma concentrations of apoB-48-containing lipoproteins in familial hypercholesterolemia is independent of PCSK9 levels
Drouin-Chartier J P, et al.
Lipids in Health and Disease, 16(1), 119-119 (2017)
From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications.
Navarese E P, et al.
European heart journal. Cardiovascular pharmacotherapy, 2(1), 44-53 (2015)
Malaria severity: Possible influence of the E670G PCSK9 polymorphism: A preliminary case-control study in Malian children.
Arama C, et al.
PLoS ONE, 13(2), e0192850-e0192850 (2018)
What is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysis.
Qiu C, et al.
Lipids in Health and Disease, 16(1), 111-111 (2017)
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique